HIGH-VOLUME · HOSP-MID

insulin glargine Side Effects

insulin glargine (also sold as Lantus, Basaglar) is HIGH-VOLUME in this FAERS book #24 of 524 by FAERS report count. Signature opener: HOSP-MID - 26.6% mention hospitalization (62,916 reports).

Data updated 2026-05-15

236,147
FAERS reports

FAERS voluntary reports, 2001 to 2025. High volume tracks exposure and reporting culture; see methodology for de-dup rules.

insulin glargine: 26.6% mention hospitalization (62,916 reports). Death stamp DEATH-HEAVY; volume band HIGH-VOLUME #24 of 524 by FAERS report count.

High-report extract for insulin glargine (Lantus): 236,147 FAERS rows (2001-2025). Top named reactions: BLOOD GLUCOSE INCREASED, BLOOD GLUCOSE DECREASED, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION. Outcome stamps DEATH-HEAVY · HOSP-MID · SEX-BALANCED. FAERS is voluntary signal detection, not incidence.

Counts from the openFDA FAERS extract (2001–2025). Stamps MEGA-CASE · DEATH-HEAVY · HOSP-MID · SEX-BALANCED.

BLOOD GLUCOSE INCREASED leads 38,214 of 236,147 reports

BLOOD GLUCOSE INCREASED
38,214
BLOOD GLUCOSE DECREASED
10,314
INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION
9,798
NAUSEA
9,568
PRODUCT STORAGE ERROR
8,531
VISUAL IMPAIRMENT
8,514
HYPOGLYCAEMIA
7,786
DIARRHOEA
6,900
FATIGUE
6,761
INCORRECT DOSE ADMINISTERED
6,540
MALAISE
6,531
WEIGHT DECREASED
6,309
INJECTION SITE PAIN
6,248
DYSPNOEA
6,216
VOMITING
6,030
FALL
5,983
DIZZINESS
5,891
HEADACHE
5,328

Who reports · age peak 45-64 (SEX-BALANCED)

Sex coding · SEX-BALANCED

Female 120,021 (55%)
Male 98,721 (45%)
Unknown 733

Age peak 45-64 (57,639 reports)

0-17 2,493 (2%)
18-44 12,380 (8%)
45-64 57,639 (38%)
65-74 46,118 (30%)
75+ 34,616 (23%)

FAERS filings rising toward 2025

2001 2025

Reactions in Death Reports

Death-mentioned subset is HEAVY here (13,233 reports, 5.6%). Top co-reported reactions in that subset - voluntary, not causal.

Reaction Reports
DEATH 4,520
RENAL FAILURE 834
ACUTE KIDNEY INJURY 657
DYSPNOEA 633
MYOCARDIAL INFARCTION 605
PNEUMONIA 600
CARDIAC ARREST 555
SEPSIS 546
RESPIRATORY FAILURE 416
CHRONIC KIDNEY DISEASE 415
DIARRHOEA 406
NAUSEA 403
HYPOTENSION 394
ASTHENIA 381
ANAEMIA 370
FALL 368
CARDIAC FAILURE CONGESTIVE 358
HYPOGLYCAEMIA 354
CARDIO-RESPIRATORY ARREST 349
CEREBROVASCULAR ACCIDENT 346

Reactions in Hospitalization Reports

Hospitalization mid-share (62,916, 26.6%). Co-reported reactions:

Reaction Reports
BLOOD GLUCOSE INCREASED 6,484
HYPOGLYCAEMIA 3,745
FALL 3,584
DYSPNOEA 3,460
NAUSEA 3,426
PNEUMONIA 3,306
VOMITING 3,207
DIARRHOEA 2,895
ACUTE KIDNEY INJURY 2,798
ASTHENIA 2,642
FATIGUE 2,498
HYPERGLYCAEMIA 2,477
MALAISE 2,329
CEREBROVASCULAR ACCIDENT 2,245
BLOOD GLUCOSE DECREASED 2,139
DIABETIC KETOACIDOSIS 2,133
WEIGHT DECREASED 2,046
DIZZINESS 2,002
MYOCARDIAL INFARCTION 1,993
DEHYDRATION 1,992
How to read insulin glargine FAERS figures (MEGA-CASE · DEATH-HEAVY · HOSP-MID)

FAERS holds 236,147 voluntary reports linked to insulin glargine (Lantus, Basaglar, Toujeo), 2001-2025. Death is listed on 13,233 (5.6%). Hospitalization appears on 62,916 (26.6%). Top co-reported indication: Type 2 Diabetes Mellitus.

MEGA-CASE books overweight common drugs and loud reporting cultures; HOSP-MID is the page opener, not a per-patient risk.

Read with insulin glargine

Peers ranked by ABS(total_reports), then an ABS(death_share) pole; guide hop follows DEATH-HEAVY · HOSP-MID stamps.